BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Idilman R, De Maria N, Kugelmas M, Colantoni A, Van Thiel DH. Immunosuppressive drug-induced leukoencephalopathy in patients with liver transplant. Eur J Gastroenterol Hepatol. 1998;10:433-436. [PMID: 9619393 DOI: 10.1097/00042737-199805000-00015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Erin N, Lehman RA, Boyer PJ, Billingsley ML. In vitro hypoxia and excitotoxicity in human brain induce calcineurin-Bcl-2 interactions. Neuroscience 2003;117:557-65. [PMID: 12617962 DOI: 10.1016/s0306-4522(02)00934-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
2 Garg RK. Posterior leukoencephalopathy syndrome. Postgrad Med J 2001;77:24-8. [PMID: 11123390 DOI: 10.1136/pmj.77.903.24] [Cited by in Crossref: 156] [Cited by in F6Publishing: 83] [Article Influence: 7.8] [Reference Citation Analysis]
3 Bink A, Weidauer S, Hermans M, Kell C, Lanfermann H. Reversible bilateral pyramidal tract lesions after hypertensive crisis and cerebral seizures. J Neuroradiol 2007;34:340-3. [PMID: 18031813 DOI: 10.1016/j.neurad.2007.09.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
4 Stott VL, Hurrell MA, Anderson TJ. Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed: Reversible posterior leukoencephalopathyreviewed. Internal Medicine Journal 2005;35:83-90. [DOI: 10.1111/j.1445-5994.2004.00750.x] [Cited by in Crossref: 185] [Cited by in F6Publishing: 95] [Article Influence: 11.6] [Reference Citation Analysis]
5 Kastrup O, Schlamann M, Moenninghoff C, Forsting M, Goericke S. Posterior Reversible Encephalopathy Syndrome: The Spectrum of MR Imaging Patterns. Clin Neuroradiol 2015;25:161-71. [DOI: 10.1007/s00062-014-0293-7] [Cited by in Crossref: 51] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
6 Higa GM, Abraham J. Biological mechanisms of bevacizumab-associated adverse events. Expert Rev Anticancer Ther. 2009;9:999-1007. [PMID: 19589038 DOI: 10.1586/era.09.68] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
7 Liman T, Siebert E, Endres M. Kopfschmerz und Bluthochdruck: Mythos und Evidenz. Nervenarzt 2010;81:963-72. [DOI: 10.1007/s00115-010-2996-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
8 D'Angelo P, Farruggia P, Lo Bello A, Trizzino A, Tropia S, Caselli D, Aricò M. Reversible posterior leukoencephalopathy syndrome: report of 2 simultaneous cases in children. J Pediatr Hematol Oncol 2006;28:177-81. [PMID: 16679945 DOI: 10.1097/01.mph.0000210406.82050.07] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]